Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
Bajaj HS, Welch M, Shah P, et al. The Lancet 2026;407:2402-2413.
What it found
In adults with type 2 diabetes on diet and exercise alone, HbA1c fell by 1.69% to 1.94% vs 0.81% with placebo, and body weight by 11.5% to 15.3% vs 2.6%. Side effects were mainly mild to moderate gastrointestinal events; 2-5% stopped because of side effects vs 0% on placebo. No severe hypoglycaemia.
Limitations
40 weeks; participants early in their diabetes (mean 2.5 years). Sites in the USA, Mexico and India only.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.